Tearlab Corp (TEAR) Files Form 4 Insider Buying : Brock Wright Buys 59,686 Shares

Tearlab Corp (TEAR): Brock Wright , director of Tearlab Corp purchased 59,686 shares on May 27, 2016. The Insider buying transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.77 per share for a total value of $46,386.09 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Brock Wright (director) purchased 130,314 shares at $0.76 per share price.On May 11, 2016, Wes Brazell (CFO) purchased 66,666 shares at $0.00 per share price.Also, On May 11, 2016, Richard L Md Lindstrom (director) purchased 133,332 shares at $0.00 per share price.On May 11, 2016, Joseph Jensen (CEO) purchased 133,332 shares at $0.00 per share price.

Shares of TearLab Corp (TEAR) ended Friday, May 27, 2016 session in red amid volatile trading. The shares closed down -0.0234 points or -3.00% at $0.7566 with 1,45,975 shares getting traded. Post opening the session at $0.78, the shares hit an intraday low of $0.7566 and an intraday high of $0.8099 and the price vacillated in this range throughout the day. The company has a market cap of $26 M and the number of outstanding shares has been calculated to be 3,42,14,447 shares. The 52-week high of TearLab Corp is $3.0299 and the 52-week low is $0.5995.

TearLab Corp Money Flow Index Chart

Company has been under the radar of several Street Analysts.TearLab Corp is Upgraded by Feltl & Co. to Strong Buy. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 5, 2016.

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company is engaged in commercial manufacturing of the TearLab Osmolarity System. The Company’s wholly owned subsidiary TearLab Research Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries metabolites (glucose) genes and proteins) at the point-of-care. The TearLab Osmolarity System measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System is an integrated testing system consisted of: the TearLab disposable the TearLab Pen and the TearLab Reader.

Leave a Reply

TearLab Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on TearLab Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.